summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Company profile
Ticker
SMMT
Exchange
Website
CEO
Robert W. Duggan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Summit Corp plc, Summit Therapeutics plc
SEC CIK
Corporate docs
Subsidiaries
Summit (Oxford) Limited • Discuva Limited • Summit Therapeutics Sub Inc. • Summit Therapeutics Limited • Summit International Holdings Limited • Summit Therapeutics Global LLC ...
SMMT stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
11 Apr 24
8-K
Departure of Directors or Certain Officers
3 Apr 24
8-K
Other Events
22 Mar 24
8-K
Barclays 26th Annual Global Healthcare Conference Dr. Maky Zanganeh Bob Duggan CEO & President Chairman & CEO
12 Mar 24
8-K
Other Events
5 Mar 24
EFFECT
Notice of effectiveness
28 Feb 24
8-K
Summit Therapeutics Reports Financial Results and Operational Progress
20 Feb 24
S-3
Shelf registration
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Oppenheimer’s 34th Annual Healthcare Life Sciences Conference Dr. Maky Zanganeh Bob Duggan CEO & President Chairman & CEO
15 Feb 24
Transcripts
SMMT
Earnings call transcript
2023 Q4
20 Feb 24
SMMT
Earnings call transcript
2023 Q3
7 Nov 23
SMMT
Earnings call transcript
2023 Q2
9 Aug 23
SMMT
Earnings call transcript
2023 Q1
11 May 23
SMMT
Earnings call transcript
2022 Q4
9 Mar 23
SMMT
Earnings call transcript
2018 Q4
27 Mar 19
SMMT
Earnings call transcript
2018 Q2
20 Sep 18
SMMT
Earnings call transcript
2017 Q4
11 Apr 18
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.79 mm | 23.79 mm | 23.79 mm | 23.79 mm | 23.79 mm | 23.79 mm |
Cash burn (monthly) | 6.11 mm | 8.18 mm | 6.83 mm | 49.48 mm | 4.97 mm | 4.34 mm |
Cash used (since last report) | 40.80 mm | 54.66 mm | 45.63 mm | 330.53 mm | 33.17 mm | 29.01 mm |
Cash remaining | -17.01 mm | -30.86 mm | -21.84 mm | -306.74 mm | -9.38 mm | -5.22 mm |
Runway (months of cash) | -2.8 | -3.8 | -3.2 | -6.2 | -1.9 | -1.2 |
Institutional ownership, Q3 2023
8.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 91 |
Opened positions | 7 |
Closed positions | 13 |
Increased positions | 33 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 59.22 bn |
Total shares | 57.16 mm |
Total puts | 21.70 k |
Total calls | 587.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Zanganeh Maky | 24.89 mm | $37.83 mm |
BLK Blackrock | 8.98 mm | $16.79 bn |
Vanguard | 6.10 mm | $11.40 bn |
Baker Bros. Advisors | 3.14 mm | $5.87 bn |
Geode Capital Management | 2.96 mm | $5.53 bn |
STT State Street | 2.27 mm | $4.24 bn |
NTRS Northern Trust | 1.07 mm | $2.00 bn |
Charles Schwab Investment Management | 940.80 k | $1.76 bn |
Steward Partners Investment Advisory | 650.00 k | $1.22 bn |
MS Morgan Stanley | 555.34 k | $1.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Ronaghi Mostafa | Stock Option Common Stock | Grant | Acquire A | No | No | 4.03 | 25,315 | 102.02 k | 225,315 |
11 Apr 24 | Ronaghi Mostafa | Stock Option Common Stock | Grant | Acquire A | No | No | 4.03 | 200,000 | 806.00 k | 200,000 |
2 Apr 24 | Bhaskar Anand | Stock Option Common Stock | Grant | Acquire A | No | No | 3.85 | 600,000 | 2.31 mm | 600,000 |
2 Apr 24 | Soni Manmeet Singh | Stock Option Common Stock | Grant | Acquire A | No | No | 3.85 | 1,100,000 | 4.24 mm | 1,100,000 |
News
Director of Lululemon Purchases Shares After Large Drop – Insider Weekends
2 Apr 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
26 Mar 24
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
26 Mar 24
Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $8
26 Mar 24
Press releases
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
11 Apr 24
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
9 Apr 24
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
22 Mar 24
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
14 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
11 Mar 24